top of page
News, Events and Updates
Search
Mar 25, 2014
A novel multipotent sigma 1/M1 muscarinic activator for a comprehensive therapeutic strategy in AD
Mar 18, 2014
Anavex Successfully Closes $10M Financing to Initiate Phase 1b/2a Alzheimer's Clinical Trial
Mar 12, 2014
Anavex Announces $10M Private Placement of Convertible Debentures
Mar 9, 2014
Anavex Encouraged By Scientific Data Confirming Sigma-1 Receptor Agonist Extends Survival in ALS
Mar 4, 2014
Anavex: Research Report Reveals Cardioprotective Action of Sigma-1 Receptor Agonists
Feb 26, 2014
Research Report Confirms Opportunity for Anavex Anti-Cancer and Neuropathic Pain Compounds
Feb 3, 2014
Anavex to Present at 16th Annual BIO CEO & Investor Conference
Jan 23, 2014
Sigma-1 Receptor Implicated in Cell Survival of Rare Neurodegenerative Diseases
Jan 13, 2014
Anavex Agreement with the Roskamp Institute to Advance the Clinical Development of ANAVEX PLUS
Jan 7, 2014
Anavex CEO Invited to Present at Upcoming Investment Conferences
Dec 11, 2013
The Anticipated Clinical Effect of the new AD Drug ANAVEX 2-73 in a Calibrated Quantitative Systems
38
39
40
41
42
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
